INVESTOR RELATIONS

As featured in the media
Latest Announcements

* For additional information about share price and latest announcements please review HeraMED’s page on the ASX platform View Page

  • Appendix 2A & Cleansing Notice10/02/2021View
  • Israel’s Largest Healthcare Provider Begins Pilot Study08/02/2021View
  • Proposed issue of Securities – HMD04/02/2021View
  • Proposed issue of Securities – HMD04/02/2021View
  • Completion of AUD 2.3M Placement04/02/2021View
  • Trading Halt02/02/2021View
  • Quarterly Activities & Cashflow Report29/01/2021View
  • Hapvida Extends Subscription on new SaaS Terms26/01/2021View
  • Updated HeraMED Investor Update Conference Call17/12/2020View
  • HeraMED Investor Update Conference Call 17/12/2020View
  • Mayo Clinic approves Clinical Study of HeraBEAT 15/12/2020View
  • Partnership to Launch HeraCARE & HeraBEAT with Teleperinatal 15/12/2020View
  • Appendix 2A14/12/2020View
  • Release from escrow23/11/2020View
  • Partnership with eCare21 – Additional Information 16/11/2020View
  • Partnership with eCare21 & functional integration complet08/11/2020View
  • Quarterly Activities & Cashflow Report29/10/2020View
  • Amended Updated Investor Presentation21/10/2020View
  • Updated Investor Presentation21/10/2020View
  • HMD Clinical Study Results Conference Call08/10/2020View
  • Clinical & Functional Validation of HeraBEAT Achieved at JHC08/10/2020View
  • Partnership with Leading Virtual Care Platform eCare21 in US16/09/2020View
  • Appendix 2A07/09/2020View
  • Enrolment in Clinical Study at JHC Completed Ahead Schedule03/09/2020View
  • Appendix 4D and Half Year Report25/08/2020View
  • Proposed issue of Securities – HMD14/08/2020View
  • Proposed issue of Securities – HMD14/08/2020View
  • Appendix 2A11/08/2020View
  • Appendix 2A11/08/2020View
  • Cleansing Notice05/08/2020View
  • Proposed issue of Securities – HMD05/08/2020View
  • Successful Placement of SPP Shortfall05/08/2020View
  • Updated Quarterly Activities Report03/08/2020View
  • Change of Director’s Interest Notice03/08/2020View
  • Quarterly Activities & Cashflow Report29/07/2020View
  • Study Commenced & Recruitment Initiated – Joondalup Campus27/07/2020View
  • Change of Director’s Interest Notice23/07/2020View
  • Appendix 2A21/07/2020View
  • Reinstatement to Official Quotation21/07/2020View
  • Proposed issue of Securities – HMD21/07/2020View
  • Proposed issue of Securities – HMD21/07/2020View
  • Proposed issue of Securities – HMD21/07/2020View
  • HeraMED Extends its Collaboration with Mayo Clinic21/07/2020View
  • Suspension from Official Quotation20/07/2020View
  • Trading Halt16/07/2020View
  • Pause In Trading16/07/2020View
  • Results of Annual General Meeting14/07/2020View
  • Results of Share Purchase Plan Offer13/07/2020View
  • Final Approvals Received to Commence Clinical Study13/07/2020View
  • Update on HMD SPP Offer25/06/2020View
  • Becoming a substantial holder24/06/2020View
  • Appendix 2A and Cleansing Notice15/06/2020View
  • Letter to Shareholders regarding Notice of AGM12/06/2020View
  • Notice of Annual General Meeting/Proxy Form12/06/2020View
  • HMD SPP Offer Booklet and Application Form12/06/2020View
  • SPP Cleansing Notice12/06/2020View
  • Appendix 3B05/06/2020View
  • Company Presentation – June 202005/06/2020View
  • HMD Raises $2.32 Million and Launches SPP05/06/2020View
  • Trading Halt01/06/2020View
  • Agreement with Freeman Rd & PHI Group – Pilots in Australia20/05/2020View
  • Exclusive Agreement Executed with Australian Distributor08/05/2020View
  • Quarterly Activities and CashFlow Report01/05/2020View
  • New FDA Recommendations – Fetal & Maternal Monitoring27/04/2020View
  • Appendix 2A & Cleansing Notice17/04/2020View
  • US Market Entry Strategy Update07/04/2020View
  • US Market Strategy Presentation – April 202007/04/2020View
  • Appendix 4G and Corporate Governance Statement27/03/2020View
  • Annual Report to shareholders27/03/2020View
  • HMD Update & COVID-19 Opportunities Conference Call25/03/2020View
  • Company Update – COVID-19 To Accelerate Global Opportunities24/03/2020 View
  • HeraCARE Product Development Update02/03/2020 View
  • HeraCARE Presentation – March 202002/03/2020 View
  • Change of Company Secretary & Registered Address02/03/2020 View
  • Appendix 4E & Preliminary Final Report27/02/2020 View
  • Cleansing Notice20/02/2020 View
  • Appendix 2A19/02/2020 View
  • Proposed issue of Securities – HMD19/02/2020View
  • Results of General Meeting19/02/2020View
  • HeraBEAT Plus Clinical Trial Study Details17/02/2020View
  • Mayo Clinic clinical study to evaluate HeraBEAT Plus10/02/2020View
  • HeraMED appoints US General Manager of Operations03/02/2020View
  • December Quarter Activities Report and Appendix 4C30/01/2020View
  • Notice of Extraordinary General Meeting and Proxy Form20/01/2020View
  • HMD accesses unique pregnancy database to strengthen OrionAI20/01/2020View
  • Response to ASX Aware Query20/01/2020View
  • Update on Voluntary Escrow for Minor Vendor Options09/01/2020View
  • Cleansing Notice17/12/2019View
  • Appendix 3B17/12/2019View
  • Appendix 3B12/12/2019View
  • A$1.42m strategic placement completed to expedite US entry10/12/2019View
  • Trading Halt06/12/2019View
  • New CPT codes allow for potential reimbursement in USA04/12/2019View
  • 2020 Company Outlook02/12/2019View
  • Change of Director’s Interest Notice – Tal Slonim28/11/2019View
  • Change of Director’s Interest Notice – David Groberman28/11/2019View
  • Appendix 3B and ASX Escrow Release28/11/2019View
  • Indian Hospital Group Cooperates with H-Cube and HeraMED25/11/2019View
  • Release of Securities from ASX Escrow Restriction20/11/2019View
  • HeraMED Receives FDA 510(k) Clearance for HeraBEAT Device18/11/2019View
  • Retraction of Statements – Next Tech Stock Article15/11/2019View
  • Trading Halt15/11/2019View
  • Pause in Trade15/11/2019View
  • Response to ASX Price and Volume Query14/11/2019View
  • Trading Halt14/11/2019View
  • Pause in Trading14/11/2019View
  • Hapvida Saude (Brazil) Trial Update07/11/2019View
  • Appendix 3B05/11/2019View
  • September Quarter Activities Report and Appendix 4C30/10/2019View
  • Market entry for HeraBEAT and HeraCARE Progresses in India25/10/2019View
  • HeraCARE – the digital era of pregnancy care14/10/2019View
  • Collaboration agreement secured with IntMED Software Ltd ME02/10/2019View
  • HMD passes first stage for Israel Innovation Authority Grant24/09/2019View
  • HeraMED and Mayo Clinic to co-develop a New Platform17/09/2019View
  • Global Distribution Progress Update04/09/2019View
  • Appendix 3B28/08/2019View
  • HeraMED Solutions Operational Across Multiple Hapvida Sites28/08/2019View
  • Appendix 4D and Half Year Report28/08/2019View
  • Correction to Appendix 4C14/08/2019View
  • HeraMED enters the German market with initial PO secured12/08/2019View
  • June Quarterly Activities Report & Appendix 4C31/07/2019View
  • HeraCARE Investor Presentation July 201922/07/2019View
  • HeraCARE PRO Integrated into Hapvidas Hospital Systems01/07/2019View
  • HeraBEAT Australian B2C launch underway19/06/2019View
  • Appendix 3B14/06/2019View
  • Appendix 3B06/06/2019View
  • Appendix 3B03/06/2019View
  • Release of Securities from Escrow31/05/2019View
  • Results of Annual General Meeting29/05/2019View
  • Annual General Meeting Venue Room Update24/05/2019View
  • Dr Friedman joins HeraMED advisory board20/05/2019View
  • HeraMED to launch HeraBEAT in Mexico15/05/2019View
  • Company Presentation May 201914/05/2019View
  • Release of Securities from Escrow09/05/2019View
  • HeraMED Expands European Distribution Network Clarification08/05/2019View
  • HeraMED Expands European Distribution Network08/05/2019View
  • HeraMED begins FDA Approval Process for HeraBEAT29/04/2019View
  • Notice of Annual General Meeting and Proxy Form26/04/2019View
  • March Quarterly Activity Report & Appendix 4C26/04/2019View
  • Meerkats Partners for HeraBEATs Australian B2C Launch16/04/2019View
  • HeraMED launches HeraBEAT in the United Kingdom11/04/2019View
  • Response to ASX Query – Annual Report as at 31/12/1808/04/2019View
  • Addendum to Annual Report05/04/2019View
  • Appendix 4G29/03/2019View
  • Annual Report29/03/2019View
  • Orion Artificial Intelligence Presentation26/03/2019View
  • Dr Arturo Weschler MD Appointed to Lead Orion AI Operations26/03/2019View
  • Quasar Manufacturing Agreement to Deliver Scale & Efficiency13/03/2019View
  • Appendix 4E & Preliminary Final Report28/02/2019View
  • Major Brazilian Health Care Group Places Initial Pilot Order14/02/2019View
  • December Quarterly Activity Report & Appendix 4C31/01/2019View
  • Australian Distribution Agreement for 9000 HeraBEAT Units14/01/2019View
  • December Investor Presentation19/12/2018View
  • Becoming a substantial holder – Holley Pharmaceutical Group19/12/2018View
  • HeraMED Completes Over-Subscribed $6 Million IPO12/12/2018View
  • Becoming a substantial holder – Tal Slonim11/12/2018View
  • Becoming a substantial holder – David Groberman11/12/2018View
  • Initial Director’s Interest Notice – Tal Slonim11/12/2018View
  • Initial Director’s Interest Notice – Ronald Weinberger11/12/2018View
  • Initial Director’s Interest Notice – Doron Birger11/12/2018View
  • Initial Director’s Interest Notice – David Hinton11/12/2018View
  • Initial Director’s Interest Notice – David Groberman11/12/2018View
  • Statement of Confirmations10/12/2018View
  • Updated Statement of Commitments10/12/2018View
  • Voluntary Escrow10/12/2018View
  • Restricted Securities10/12/2018View
  • Updated Pro Forma Statement of Financial Position10/12/2018View
  • Capital Structure10/12/2018View
  • Securities Trading Policy10/12/2018View
  • Hera Med Ltd. Half Yearly Accounts to 30 June 201810/12/2018View
  • Hera Med Ltd. 2016 and 2017 Full Year Accounts10/12/2018View
  • Supplementary Prospectus10/12/2018View
  • Prospectus10/12/2018View
  • Constitution10/12/2018View
  • Appendix 1A and Information Form and Checklist10/12/2018View
  • Top 20 Holders10/12/2018View
  • Distribution Schedule10/12/2018View
  • ASX Notice – Admission to Official List10/12/2018View